期刊文献+

抗PD-1/PD-L1药物治疗肿瘤耐药机制研究进展 被引量:5

下载PDF
导出
摘要 PD-1/PD-L1通路可通过多种机制产生免疫抑制作用,介导肿瘤免疫逃逸。目前针对PD-1/PD-L1通路的研究已成为近几年的热点。区别于传统的化疗及放疗,抗PD-1/抗PD-L1药物介导的免疫靶向治疗,能更加有效地调动机体本身的抗肿瘤免疫能力,改善免疫微环境,在肺癌、黑色素瘤、胃癌等恶性肿瘤治疗中取得了显著效果。但目前抗PD-1/抗PD-L1药物治疗并非所有患者均能获益,部分患者存在原发性耐药,有的患者出现继发性耐药。本文就抗PD-1/PD-L1药物治疗的耐药机制作一综述。
出处 《癌症进展》 2017年第12期1365-1368,1374,共5页 Oncology Progress
  • 相关文献

参考文献3

二级参考文献51

  • 1Stéphanie Delluc,Patricia Hachem,Sylvie Rusakiewicz,Auguste Gaston,Carmen Marchiol-Fournigault,Lea Tourneur,Narjes Babchia,Didier Fradelizi,Armelle Regnault,Kim Hanh Quan Sang,Gilles Chiocchia,Agnès Buzyn.Dramatic efficacy improvement of a DC-based vaccine against AML by CD25 T cell depletion allowing the induction of a long-lasting T cell response[J]. Cancer Immunology, Immunotherapy . 2009 (10) 被引量:1
  • 2Ahmed MS,Bae YS.Dendritic cell-based therapeutic cancer vaccines:past,present and future. Clin Exp Vaccine Res . 2014 被引量:1
  • 3Ralph M. Steinman.Decisions About Dendritic Cells: Past, Present, and Future. ANNUAL REVIEW OF IMMUNOLOGY;Annual Review of Immunology . 2012 被引量:1
  • 4Eijiro Nagasaki,Akitaka Takahara,Shigeo Koido.Combined Treatment With Dendritic Cells and 5-fluorouracil Elicits Augmented NK Cell-mediated Antitumor Activity Through the Tumor Necrosis Factor-alpha Pathway. JOURNAL OF IMMUNOTHERAPY . 2010 被引量:1
  • 5Shimizu Kanako,Fujii Shin-ichiro.DC therapy induces long-term NK reactivity to tumors via host DC. European journal of immunology . 2009 被引量:1
  • 6Lion Eva,Smits Evelien L J M,Berneman Zwi N,Van Tendeloo Viggo F I.NK cells: key to success of DC-based cancer vaccines?. The Oncologist . 2012 被引量:1
  • 7Jeanette E. Boudreau,Kyle B. Stephenson,Fuan Wang.IL-15 and Type I Interferon Are Required for Activation of Tumoricidal NK Cells by Virus-Infected Dendritic Cells. Cancer Research . 2011 被引量:1
  • 8Boudreau Jeanette E,Bridle Byram W,Stephenson Kyle B,Jenkins Kristina M,Brunellière Jér?me,Bramson Jonathan L,Lichty Brian D,Wan Yonghong.Recombinant vesicular stomatitis virus transduction of dendritic cells enhances their ability to prime innate and adaptive antitumor immunity. Molecular therapy : the journal of the American Society of Gene Therapy . 2009 被引量:1
  • 9SHIMIZU K,ASAKURA M,FUJII S.Prolonged antitumor NK cell reactivity elicited by CXCL10-expressing dendritic cells licensed by CD40L+CD4+memory T cells. J Immunol . 2011 被引量:1
  • 10朱学军,李晓惠,夏雯,张文曦,陈健一.人外周血树突状细胞体外稳定、高效培养的新方法[J].中国肿瘤生物治疗杂志,2007,14(6):575-577. 被引量:5

共引文献9

同被引文献34

引证文献5

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部